Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
The association of single-nucleotide polymorphisms (SNPs) of B-cell activating factor (BAFF)/a proliferation-inducing ligand (APRIL) system with B-cell chronic lymphocytic leukemia (B-CLL) have been suggested, therefore, we investigated 20 SNPs of BAFF, APRIL, BAFF-R, transmembrane activator and calcium modulator and cyclophilin-ligand interactor (TACI), B-cell maturation antigen (BCMA) genes and the risk and outcome of B-CLL in 187 patients and 296 healthy subjects as well as ligand-receptor gene × gene interactions. Although the obtained P-values for all 20 SNPs did not reach statistical significance for this study (α = 0.003), the high value of the global chi-squared statistic (χ(2) df = 38  = 52.65; P = 0.0586), and obtained values of odds ratio indicate that rs9514828 (BAFF), rs3803800 (APRIL) and rs4985726 (TACI) may be associated with the risk of B-CLL. We observed that the B-CLL patients with the genotype rs9514828CT/rs11570136AA were diagnosed with the disease 12 years later than the whole group of patients in this study.
Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
M
M
Jasek
Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
M
M
Wagner
Department of Genomics, Faculty of Biotechnology, University of Wrocław, Wroclaw, Poland.
M
M
Sobczynski
Department of Hematology, Neoplastic Diseases & Bone Marrow Transplantation, Medical University, Wroclaw, Poland.
D
D
Wolowiec
Department of Hematology, Neoplastic Diseases & Bone Marrow Transplantation, Medical University, Wroclaw, Poland.
K
K
Kuliczkowski
Department of Hematology, State Hospital, Opole, Poland.
D
D
Woszczyk
Department of Hematology, Neoplastic Diseases & Bone Marrow Transplantation, Medical University, Wroclaw, Poland.
M
M
Kielbinski
Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
P
P
Kusnierczyk
Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland.
I
I
Frydecka
Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland.|Department of Clinical Urology, Wroclaw Medical University, Wroclaw, Poland.
L
L
Karabon
D000368:Aged; D053264:B-Cell Activating Factor / Q000235:genetics* / Q000276:immunology; D053265:B-Cell Activation Factor Receptor / Q000235:genetics / Q000276:immunology; D053301:B-Cell Maturation Antigen / Q000235:genetics / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D015870:Gene Expression; D020022:Genetic Predisposition to Disease; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011044:Poland; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D053303:Transmembrane Activator and CAML Interactor Protein / Q000235:genetics* / Q000276:immunology; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000235:genetics* / Q000276:immunology
D053264:B-Cell Activating Factor; D053265:B-Cell Activation Factor Receptor; D053301:B-Cell Maturation Antigen; C108467:TNFRSF13B protein, human; C435926:TNFRSF13C protein, human; C086966:TNFRSF17 protein, human; C114631:TNFSF13 protein, human; C505719:TNFSF13B protein, human; D053303:Transmembrane Activator and CAML Interactor Protein; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13
B-cell activating factor; B-cell activating factor receptor; B-cell chronic lymphocytic leukemia; B-cell maturation antigen; a proliferation-inducing ligand; interactions; polymorphisms; transmembrane activator and calcium modulator and cyclophilin-ligand interactor